ArthroCare Corporation (ARTC) - NASDAQ
ARTC is defunct.
  • Feb. 3, 2014, 2:25 AM
    • Smith & Nephew (SNN) has agreed to acquire ArthroCare (ARTC) for $1.7B in a move that Smith & Nephew says will strengthen its global sports medicine business.
    • Smith & Nephew is offering $48.25 a share, 6.3% above ArthroCare's closing price of $45.38 on Friday. (PR)
    | Feb. 3, 2014, 2:25 AM
  • Jan. 8, 2014, 2:09 PM
    • "We believe the stock will trade less on fundamentals and more on the take-out potential, [so] we once again put pen to paper to provide clarity on what we feel the different buyers are willing/able to pay," Canaccord says, regarding the outlook for ArthroCare (ARTC +18.8%) in the wake of the DPA announced Tuesday.
    • Analyst William Plovanic says the shares could be valued at "above $55 for an acquirer that planned on keeping most infrastructure."
    • For potential suitors with "existing infrastructure in sports med and ENT," Plovanic sees $80+.
    | Jan. 8, 2014, 2:09 PM
  • Jul. 2, 2013, 9:29 AM

    ArthroCare (ARTC) acquires privately held ENTrigue Surgical for $45M in cash. (PR)

    | Jul. 2, 2013, 9:29 AM
  • Apr. 28, 2011, 10:37 AM

    Johnson & Johnson’s (JNJ -0.9%) newfound dominance of the orthopedic device market from its $21.3B acquisition of Synthes may pressure rivals Zimmer (ZMH +3.3%) and Stryker (SYK +0.2%) to seek purchases of their own among smaller ortho companies. Potential targets: ARTC, BMTI, WMGI.

    | Apr. 28, 2011, 10:37 AM
Company Description
ArthroCare Corporation develops, manufactures and markets minimally invasive surgical products, many of which are based on its patented Coblation(r) technology. The Company's business consists of two core product areas: Sports Medicine and ENT.
Sector: Healthcare
Industry: Medical Appliances & Equipment
Country: United States